Homologous recombination technology R&D start-up completes a $7 mil. first round of venture capital financing. Investors include Stanford University. "We have implemented an aggressive product development plan, with particular emphasis on genetic modification of cells to allow the manufacture of human therapeutic proteins and genetic modification of cells to create 'universal donor cell' transplant products," the Foster City, California-based company says.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.